US 12,318,577 B2
System and method for adjusting insulin delivery
Bryan Mazlish, Palo Alto, CA (US); Lane Desborough, Thousand Oaks, CA (US); and Ross Naylor, Fullerton, CA (US)
Assigned to Insulet Corporation, Acton, MA (US)
Filed by Insulet Corporation, Acton, MA (US)
Filed on Aug. 31, 2020, as Appl. No. 17/007,305.
Application 17/007,305 is a continuation of application No. 15/870,646, filed on Jan. 12, 2018, granted, now 10,758,675.
Claims priority of provisional application 62/446,239, filed on Jan. 13, 2017.
Prior Publication US 2020/0397989 A1, Dec. 24, 2020
Int. Cl. A61M 5/172 (2006.01); A61M 5/142 (2006.01); A61M 5/158 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/30 (2018.01); A61M 5/145 (2006.01)
CPC A61M 5/1723 (2013.01) [A61M 5/14248 (2013.01); A61M 5/158 (2013.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/30 (2018.01); A61M 2005/14208 (2013.01); A61M 2005/14268 (2013.01); A61M 5/1452 (2013.01); A61M 2005/1586 (2013.01); A61M 2205/3313 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/502 (2013.01); A61M 2230/201 (2013.01)] 40 Claims
OG exemplary drawing
 
1. A method of delivering insulin, the method comprising:
generating an indication that a probability of occurrence of an undesirable event exceeds a threshold responsive to a prediction by an event model; and
generating a recommended change to a personalization setting of an insulin therapy responsive to the indication,
wherein the event model is configured to predict an occurrence of the undesirable event responsive to a difference between a personalized model that represents a user's physiological response to insulin therapy and a generalized model that represents a generalized physiological response by a general population to an insulin therapy.